Financial Post EN

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Full Year 2025 LUPKYNIS Sales Grew 25% Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial Results Total […]

Feb 26, 2026 &02002626202628; 11:00 UTC financialpost.com Trending 4/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +80/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Aurinia Pharmaceuticals riporta una crescita delle vendite del farmaco LUPKYNIS del 25% nell'anno 2025 e fornisce una guida ottimistica per il 2026 con previsioni di vendite tra 305 e 315 milioni di dollari. I risultati finanziari e le prospettive future indicano una solida performance operativa e una crescita sostenuta del prodotto principale.

AI CONFIDENCE

0% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

AUPH

AUPHStock

Expected to rise

Crescita del 25% delle vendite di LUPKYNIS nel 2025 e guida positiva per il 2026 (305-315 milioni di dollari), che supera le aspettative del mercato e indica un'accelerazione della traiettoria di crescita.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Considerare un'accumulazione graduale in caso di pullback, con obiettivo di medio termine basato sulla crescita sostenuta del prodotto flagship. Monitorare l'andamento delle vendite trimestrali rispetto alla guida.

KEY SIGNALS

Crescita annuale vendite LUPKYNIS +25%Guida 2026 superiore alle stimeRisultati finanziari solidi

SECTORS INVOLVED

biotecnologiefarmaceutico

Analysis generated on Feb 26, 2026 at 21:39 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

RELATED INTELLIGENCE